![\"\"](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/Novartis_Vasant-Vas-Narasimhan-970.jpg\")
<\/p>\n <\/p>\n
Novartis CEO Vas Narasimhan, M.D. [Photo: Novartis]<\/p>\n
Swiss global pharmaceutical giant Novartis plans to build a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton. This purpose-built RLT site will be the company\u2019s fifth in the U.S. and first manufacturing facility in Texas, marking further progress in the company\u2019s goal of hitting $23 billion in U.S. investment.
\u00a0
The North Texas facility is expected to create new jobs in bioengineering, advanced manufacturing, quality, and operations, bolstering economic growth in Denton and surrounding communities. Construction is scheduled to begin this year, with the site slated for completion in 2028.
\u00a0
\u201cRLT has the potential to revolutionize cancer care,\u201d Novartis CEO Vas Narasimhan said in a statement. \u201cThe addition of our fifth RLT manufacturing site in the U.S. strengthens our ability to meet growing demand, building the capabilities needed to deliver these next-generation treatments with the speed and precision they require.\u201d<\/p>\n
RLT\u00a0 therapy precisely delivers radiation to cancer cells<\/p>\n
Radioligand therapy uses radioactive substances to precisely deliver radiation to cancer cells, minimizing harm to healthy cells.<\/p>\n
The Texas site will join a comprehensive Novartis RLT manufacturing network\u2014with existing U.S. sites in New Jersey, Indiana, and California and a recently announced site to be constructed in Florida\u2014providing \u201coutstanding RLT capacity from coast to coast,\u201d the company said. The manufacturing network has a longstanding record of allowing more than 99% of doses to be administered on the planned day. Each dose of RLT is custom-made and time-sensitive, making proximity to patients and treatment centers critical, Novartis said.<\/p>\n
Novartis said it\u2019s improving cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT delivers treatment directly to targeted cancer cells anywhere in the body.\u00a0\u00a0<\/p>\n
Novartis is actively investigating new applications of RLTs across cancer types and settings, with one of the deepest and most advanced pipelines in the industry, with trials in prostate cancer, breast, colon, lung, brain, pancreatic, and other cancers. Novartis said it has established global expertise, with specialized supply chain and manufacturing capabilities throughout its network of RLT production sites around the world.<\/p>\n
Governor calls North Texas \u2018a leading biotech hub\u2019<\/p>\n
State and local leaders touted the new site for its positive impact on the economy and health.<\/p>\n
\u201cTexas is a leading biotech hub and home to groundbreaking advancements in medicine,\u201d Governor Greg Abbott said in a statement. \u201cThis significant investment by Novartis in Denton will establish their first manufacturing facility in Texas for cancer therapies and create good-paying jobs in bioengineering, advanced manufacturing, and more.\u201d<\/p>\n
\u201cWorking together with innovative global leaders,\u201d he added, \u201cwe\u2019ll continue to strengthen critical supply chains to help speed next-generation treatments to patients across Texas and the U.S.\u201d<\/p>\n
Area business leaders also praised the move as \u201can exciting win\u201d for North Texas\u2019 growing life sciences ecosystem and for patients across Texas and the U.S.<\/p>\n
Dallas Regional Chamber President & CEO Brad Cheves said Novartis\u2019 investment in Denton \u201cpowerfully underscores North Texas\u2019 status as a destination region for companies on the leading edge of innovation.\u201d<\/p>\n
\u201cRadioligand therapy represents the forefront of cancer innovation,\u201d Cheves added, \u201cand the decision to manufacture this breakthrough technology in the Dallas-Fort Worth region underscores the scale, talent and infrastructure that define our market.\u201d<\/p>\n
Cheves also pointed out the positive impact on the region\u2019s workforce.<\/p>\n
\u201cAdvanced nuclear medicine manufacturing demands precision, a highly skilled workforce and a supply chain that moves quickly and reliably,\u201d he said. \u201cWith strong higher education and industry partnerships and the ability to reach more than 50 million people within an hour\u2019s flight, DFW offers the connectivity and speed companies need to serve patients nationwide.\u201d<\/p>\n
Novartis\u2019 announcement \u201creflects years of focused, regional collaboration to grow our life sciences sector, an effort the Dallas Regional Chamber has been proud to help lead,\u201d Cheves added. \u201cWe\u2019re excited to welcome Novartis to our community and congratulate the Denton City Council and the City of Denton\u2019s Economic Development team for securing this top-tier addition to our region\u2019s booming life sciences ecosystem.\u201d<\/p>\n
Don\u2019t miss what\u2019s next. Subscribe\u00a0to\u00a0Dallas\u00a0Innovates.<\/p>\n
Track Dallas-Fort Worth\u2019s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.<\/p>\n
\u00a0<\/p>\n
\tR E A D\u00a0\u00a0 N E X T\t<\/p>\n
\t The North Texas biotech, which uses AI to accelerate cancer drug development, received FDA feedback to advance a new clinical study targeting a rare childhood brain tumor.<\/p>\n![\"\"](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/Brain-Child-iStock-2236153421.jpg\")
<\/a><\/p>\n
![\"\"](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/InterActTherapeutics-2up-970.jpg\")
<\/a><\/p>\n![\"\"](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/02\/funding-research-iStock-1139090560-970x464.jpg\")
<\/a><\/p>\n